Sort   by:  
 Page size 
ProteomicsKMT2A-rearranged leukemia proteomics
Activating mutations in kinase/PI3K/RAS signaling pathways are common in acute leukemia with KMT2A rearrangements (KMT2A-R). These mutations are often subclonal and their biological impact remain unclear. Using a retroviral acute myeloid leukemia model, we demonstrate that NRASG12D, FLT3ITD, and FLT...
ORGANISM(S): Mus musculus (Mouse) 
2018-05-02 | PXD008213 | Pride
Leukemia Mouse Tmt 
TranscriptomicsFusion gene KMT2A::SEPTIN6 in AML cell line KOPM-88
KMT2A (alias MLL) is located at chromosomal position 11q23 and en-codes histone methyltransferase 2A which activates genes via methylation of histone H3 lysine K4 in their chromatin. Mutations of KMT2A, including partial tandem duplication (PTD) and fusion with partner genes are present in both lymp...
ORGANISM(S): Homo sapiens 
2026-06-29 | E-MTAB-17091 | biostudies-arrayexpress
ProteomicsImmunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
Pharmacologic targeting of epigenetic protein complexes has shown significant in vitro responses in acute myeloid leukemia (AML). Early clinical trials in KMT2A-rearranged leukemia indicate rather transient responses and development of resistance. In an effort to define functional dependencies of KM...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD041245 | Pride
Aml Mll-fusion Kmt2a Immunoproteasome Leukemia Proteome 
ProteomicsPhosphoproteomics of primary acute myeloid leukemia cells with rearranged KMT2A
Acute myeloid leukemia (AML) is a disease with poor outcome but patients harbouring certain chromosomal rearrangements or complex karyotypes have particularly adverse prognosis. For these patients, targeted therapies have not yet made a significant clinical impact. To understand the molecular landsc...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD036669 | Pride
Aml Phosphoproteomics Genomics Kmt2a Impdh Drug screen Nucleolus Proteomics 
ProteomicsPhosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
Acute myeloid leukemia (AML) is a disease with poor outcome but patients harbouring certain chromosomal rearrangements or complex karyotypes have particularly adverse prognosis. For these patients, targeted therapies have not yet made a significant clinical impact. To understand the molecular landsc...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD032980 | Pride
Aml Phosphoproteomics Genomics Kmt2a Impdh Drug screen Nucleolus Proteomics 
GenomicsEffect of methionine restriction on gene expression of non-KMT2A-rearranged NALM-6 and KMT2A-rearranged SEM BCP-ALL cell lines
Effect of methionine restriction on gene expression of non-KMT2A-rearranged NALM-6 and KMT2A-rearranged SEM BCP-ALL cell lines
PRJNA983272 | ENA
UnknownPan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
Not available
S-EPMC7581494 | biostudies-literature
GenomicsKMT2A oncoproteins induce epigenetic resistance to targeted therapies.
KMT2A oncoproteins induce epigenetic resistance to targeted therapies.
PRJNA1060315 | ENA
GenomicsRUNX2 is a dependency factor in immature and KMT2A-rearranged T-cell acute lymphoblastic leukemia [KMT2A-MLLT1_ Runx2 ko RNA-seq]
RUNX2 is a dependency factor in immature and KMT2A-rearranged T-cell acute lymphoblastic leukemia [KMT2A-MLLT1_ Runx2 ko RNA-seq]
PRJNA637337 | ENA
GenomicsFusion gene KMT2A::SEPTIN6 in AML cell line KOPM-88
Fusion gene KMT2A::SEPTIN6 in AML cell line KOPM-88
PRJEB113686 | ENA
Sort   by:  
 Page size